CN1329389C - 化合物和它们的用途 - Google Patents

化合物和它们的用途 Download PDF

Info

Publication number
CN1329389C
CN1329389C CNB038112493A CN03811249A CN1329389C CN 1329389 C CN1329389 C CN 1329389C CN B038112493 A CNB038112493 A CN B038112493A CN 03811249 A CN03811249 A CN 03811249A CN 1329389 C CN1329389 C CN 1329389C
Authority
CN
China
Prior art keywords
trifluoromethyl
piperazine
pyridin
acetate
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038112493A
Other languages
English (en)
Chinese (zh)
Other versions
CN1701068A (zh
Inventor
B·尼尔森
E·林伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN1701068A publication Critical patent/CN1701068A/zh
Application granted granted Critical
Publication of CN1329389C publication Critical patent/CN1329389C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Liquid Crystal Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB038112493A 2002-05-17 2003-05-16 化合物和它们的用途 Expired - Fee Related CN1329389C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE02015444 2002-05-17
SE0201544A SE0201544D0 (sv) 2002-05-17 2002-05-17 Novel compounds and thier use
US41003802P 2002-09-12 2002-09-12
US60/410,038 2002-09-12

Publications (2)

Publication Number Publication Date
CN1701068A CN1701068A (zh) 2005-11-23
CN1329389C true CN1329389C (zh) 2007-08-01

Family

ID=29552452

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038112493A Expired - Fee Related CN1329389C (zh) 2002-05-17 2003-05-16 化合物和它们的用途

Country Status (24)

Country Link
US (1) US7229997B2 (https=)
EP (1) EP1506185B1 (https=)
JP (1) JP4865221B2 (https=)
KR (1) KR20050026702A (https=)
CN (1) CN1329389C (https=)
AT (1) ATE327229T1 (https=)
AU (1) AU2003228196B2 (https=)
BR (1) BR0310077A (https=)
CA (1) CA2483619A1 (https=)
CY (1) CY1105162T1 (https=)
DE (1) DE60305484T2 (https=)
DK (1) DK1506185T3 (https=)
EA (1) EA007543B1 (https=)
ES (1) ES2263971T3 (https=)
IL (1) IL164974A0 (https=)
MX (1) MXPA04011437A (https=)
NO (1) NO20045486L (https=)
NZ (1) NZ536409A (https=)
PT (1) PT1506185E (https=)
RS (1) RS99804A (https=)
SE (1) SE0201544D0 (https=)
SI (1) SI1506185T1 (https=)
WO (1) WO2003097636A1 (https=)
ZA (1) ZA200408975B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
JP5173190B2 (ja) * 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
EP1998773A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware New therapeutic combinations for the treatment of depression
AU2007230997A1 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2402324A1 (en) * 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpiperazinylpyridazines
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
WO2008052086A1 (en) * 2006-10-24 2008-05-02 Wyeth Benzodioxane derivatives and uses thereof
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009011416A (es) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
RS52518B (sr) 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
CA2729313C (en) 2008-07-03 2016-08-30 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists
ES2622161T3 (es) * 2008-07-31 2017-07-05 Janssen Pharmaceutica, N.V. Piridinas sustituidas con piperazin-1-il-trifluorometilo como antagonistas del receptor de la dopamina 2 de disociación rápida
EA021079B1 (ru) 2009-06-15 2015-03-31 Такеда Фармасьютикал Компани Лимитед Производные пиразинооксазепина
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
TW202504600A (zh) * 2023-07-04 2025-02-01 大陸商杭州中美華東製藥有限公司 Glp1r激動劑及其中間體的製備方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078063A (en) * 1976-09-24 1978-03-07 Merck & Co., Inc. Piperazinylpyridines
US4971969A (en) * 1988-11-24 1990-11-20 Akzo N.V. Pharmaceutical composition containing 1-(mono- or bis(trifluoromethyl)-2-pyridinyl)piperazines
EP0580465A1 (fr) * 1992-06-25 1994-01-26 Sanofi Nouvelle utilisation thérapeutique d'hétérocyclyl-pipérazines comme 5-HT3 agonistes et nouveaux dérivés
CN1087901A (zh) * 1992-07-31 1994-06-15 卡比制药有限公司 新的吡啶基-和嘧啶基哌嗪衍生物
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
WO2001041701A2 (en) * 1999-12-06 2001-06-14 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665203A (ja) * 1992-06-25 1994-03-08 Elf Sanofi ピペラジンのヘテロ環誘導体
JPH0797370A (ja) * 1993-09-29 1995-04-11 Asahi Chem Ind Co Ltd ２−アルコキシピラジン誘導体およびその用途
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
CA2448729A1 (en) * 2000-11-20 2002-05-23 Biovitrum Ab Piperazinyl and piperidyl substituted heterocyclic compounds
US6498184B2 (en) * 2000-12-05 2002-12-24 Akzo Nobel N.V. Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
EP1213017A3 (en) * 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078063A (en) * 1976-09-24 1978-03-07 Merck & Co., Inc. Piperazinylpyridines
US4971969A (en) * 1988-11-24 1990-11-20 Akzo N.V. Pharmaceutical composition containing 1-(mono- or bis(trifluoromethyl)-2-pyridinyl)piperazines
EP0580465A1 (fr) * 1992-06-25 1994-01-26 Sanofi Nouvelle utilisation thérapeutique d'hétérocyclyl-pipérazines comme 5-HT3 agonistes et nouveaux dérivés
CN1087901A (zh) * 1992-07-31 1994-06-15 卡比制药有限公司 新的吡啶基-和嘧啶基哌嗪衍生物
WO1998033504A1 (en) * 1997-02-03 1998-08-06 Akzo Nobel N.V. Treatment of urinary incontinence
WO2001041701A2 (en) * 1999-12-06 2001-06-14 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antiversive effects of 5HT2C receptor agonists... R.H.P.Porter et al:,British Journal of Pharmacology,Vol.128 1999 *

Also Published As

Publication number Publication date
AU2003228196B2 (en) 2009-12-17
JP4865221B2 (ja) 2012-02-01
EA200401526A1 (ru) 2005-04-28
JP2005529926A (ja) 2005-10-06
NZ536409A (en) 2007-11-30
IL164974A0 (en) 2005-12-18
EP1506185B1 (en) 2006-05-24
PT1506185E (pt) 2006-10-31
SI1506185T1 (sl) 2006-10-31
KR20050026702A (ko) 2005-03-15
DE60305484D1 (de) 2006-06-29
CN1701068A (zh) 2005-11-23
WO2003097636A1 (en) 2003-11-27
US7229997B2 (en) 2007-06-12
DK1506185T3 (da) 2006-10-02
RS99804A (sr) 2006-12-15
CY1105162T1 (el) 2010-03-03
NO20045486L (no) 2005-02-02
BR0310077A (pt) 2005-02-22
AU2003228196A1 (en) 2003-12-02
ZA200408975B (en) 2005-11-14
ATE327229T1 (de) 2006-06-15
DE60305484T2 (de) 2006-11-09
US20030232814A1 (en) 2003-12-18
MXPA04011437A (es) 2005-02-17
EP1506185A1 (en) 2005-02-16
ES2263971T3 (es) 2006-12-16
HK1084941A1 (en) 2006-08-11
CA2483619A1 (en) 2003-11-27
SE0201544D0 (sv) 2002-05-17
EA007543B1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
CN1329389C (zh) 化合物和它们的用途
KR100831909B1 (ko) 세로토닌 5-ｈｔ2 수용체의 안타고니스트로서의피페라지닐피라진 화합물
US7812017B2 (en) 4-substituted indole and indoline compounds
JP2009280587A (ja) セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物
KR20090130090A (ko) 이미다졸리딘온 유도체
ZA200303599B (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor.
CN101679272B (zh) 作为腺苷a3受体配体的三唑并[1,5-a]喹啉类
CN100484933C (zh) 新的吡嗪化合物及其在制备用于治疗与5-羟色胺相关的疾病的药物中的用途
KR20050025628A (ko) 5-ｈｔ2ａ 수용체 관련 장애의 치료를 위한 신규피페라지닐-피라지논 유도체
HK1084941B (en) Compounds and their use
AU2002215294B2 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
JP4831966B2 (ja) ５−ｈｔ２ａ受容体関連疾患の治療のための新規ピペラジニル−ピラジノン誘導体
TWI291958B (en) Pyrazinyl-piperazine compounds, their use in the treatment of serotonin related diseases, and their preparation
US6756377B2 (en) Compounds and their use
AU2002215294A1 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084941

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070801

Termination date: 20100516